ACTengine
Phase 1/2 Recruiting
375 enrolled
DUAL-OV-CAR-NK
Phase 1/2 Recruiting
36 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2 Recruiting
612 enrolled
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2 Recruiting
100 enrolled
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Phase 1/2 Completed
229 enrolled
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase 1/2 Completed
247 enrolled 15 charts
EDO-S101
Phase 1/2 Completed
71 enrolled 39 charts
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Phase 1/2 Terminated
79 enrolled
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Phase 1/2 Terminated
79 enrolled 18 charts
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Phase 1/2 Terminated
223 enrolled 50 charts
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Phase 1/2 Completed
136 enrolled 30 charts
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Phase 1/2 Completed
155 enrolled
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Phase 1/2 Unknown
85 enrolled
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Phase 1/2 Withdrawn
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Phase 1/2 Withdrawn
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Phase 1/2 Completed
25 enrolled
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Phase 1/2 Unknown
20 enrolled
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase 1/2 Unknown
52 enrolled
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase 1/2 Completed
50 enrolled 15 charts
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase 1/2 Terminated
46 enrolled 17 charts
Veli-BRCA
Phase 1/2 Completed
49 enrolled
Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Phase 1/2 Unknown
40 enrolled
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed